Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Tuesday

Market Beat
2025.08.06 14:28
portai
I'm PortAI, I can summarize articles.

Galectin Therapeutics (NASDAQ:GALT) is set to announce its Q2 2025 earnings on August 12, with analysts expecting a loss of $0.16 per share. The company previously reported a loss of $0.15 per share, exceeding estimates. GALT shares recently traded down 1.1% to $3.55, with a market cap of $224.69 million. Institutional ownership stands at 11.68%. Analysts have upgraded GALT from 'sell' to 'hold' and set a price target of $6.00. Galectin focuses on therapies for fibrotic and cancer-related diseases, with its lead product in clinical trials.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Get Galectin Therapeutics alerts:

Galectin Therapeutics Trading Down 1.1%

GALT stock traded down $0.04 during trading on Tuesday, hitting $3.55. 32,857 shares of the company's stock were exchanged, compared to its average volume of 420,276. The business has a 50-day moving average price of $2.30 and a two-hundred day moving average price of $1.71. The stock has a market capitalization of $224.69 million, a price-to-earnings ratio of -4.93 and a beta of 0.81. Galectin Therapeutics has a 52-week low of $0.73 and a 52-week high of $3.90.

Analyst Ratings Changes

Several research analysts have commented on GALT shares. Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. HC Wainwright started coverage on Galectin Therapeutics in a research report on Tuesday, June 17th. They set a "buy" rating and a $6.00 price target on the stock.

Get Our Latest Stock Report on GALT

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Galectin Therapeutics stock. Bank of America Corp DE grew its stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,358 shares of the company's stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned approximately 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent reporting period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

Featured Stories

  • Five stocks we like better than Galectin Therapeutics
  • What Are Dividend Contenders? Investing in Dividend Contenders
  • Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?
  • Stock Dividend Cuts Happen Are You Ready?
  • META Gets Huge Upgrades: How High Analysts Think Shares Could Go
  • How to Invest in Tech Stocks and Top Tech Stocks to Consider
  • Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Galectin Therapeutics Right Now?

Before you consider Galectin Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.

While Galectin Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.